Borderline Personality Disorders - Pipeline Insight, 2025

DelveInsight’s, ''Borderline Personality Disorders - Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Borderline Personality Disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Borderline Personality Disorders Understanding

The term ‘Borderline Personality Disorder’ (BPD) refers to a psychiatric syndrome that is characterized by emotion dysregulation, impulsivity, risk-taking behavior, irritability, feelings of emptiness, self-injury and fear of abandonment, as well as unstable interpersonal relationships. Paranoid ideation and dissociative states are also transient features of the syndrome. Moreover, many patients with BPD show recurring self-injurious or suicidal behavior. BPD has a lifetime prevalence of about 6%. It is much more common in clinical settings, thus rendering BPD highly relevant for health care providers and public health in general.

BPD is often a comorbid condition of other psychiatric disorders (formerly conceptualized as axis-I disorders according to DSM-IV), foremost depression, other personality disorders, and there seems to be syndromal overlap and/or comorbidity with bipolar disorder (BD), attention deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD).

'Borderline Personality Disorders - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Borderline Personality Disorders pipeline landscape is provided which includes the disease overview and Borderline Personality Disorders treatment guidelines. The assessment part of the report embraces, in depth Borderline Personality Disorders commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Borderline Personality Disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Borderline Personality Disorders. The therapies under development are focused on novel approaches to treat/improve Borderline Personality Disorders.

Borderline Personality Disorders Emerging Drugs

Vafidemstat: Oryzon

Vafidemstat (ORY-2001) is an oral small molecule that has been optimized for CNS indications and that acts as a covalent inhibitor of the epigenetic enzyme Lysine Specific Demethylase-1, LSD1 (KDM1A). Oryzon has performed a Phase IIa clinical trial (REIMAGINE study) to assess vafidemstat’s effects on agitation-aggression in patients with different psychiatric disorders: Autism Spectrum Disorder (ASD), Borderline Personality Disorder (BPD) and adult Attention Deficit Hyperactivity Disorder (ADHD).

Borderline Personality Disorders: Therapeutic Assessment

This segment of the report provides insights about the Borderline Personality Disorders drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Borderline Personality Disorders

There are approx. 5+ key companies which are developing the therapies Borderline Personality Disorders. The companies which have their Borderline Personality Disorders drug candidates in the most advanced stage, i.e Phase II include Oryzon

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Borderline Personality Disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Borderline Personality Disorders: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Borderline Personality Disorders therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Borderline Personality Disorders drugs.

Borderline Personality Disorders Report Insights

• Borderline Personality Disorders Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Borderline Personality Disorders Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Borderline Personality Disorders drugs?
• How many Borderline Personality Disorders drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Borderline Personality Disorders?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Borderline Personality Disorders therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Borderline Personality Disorders and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Oryzon
• Boehringer Ingelheim
• Otsuka
• Intra-Cellular Therapies

Key Products

• Vafidemstat
• BI1358894
• Brexpiprazole
• Caplyta
• Rexulti

This product will be delivered within 2 business days.